{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:17:09Z","timestamp":1772507829943,"version":"3.50.1"},"reference-count":19,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2009,3,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Patients with recurrent ovarian, peritoneal, or fallopian tube cancer have limited therapeutic options. There are no reports of nanoparticle albumin\u2013bound paclitaxel (nab-paclitaxel) in patients with recurrent platinum-sensitive disease. We report efficacy and toxicity with nab-paclitaxel in this group. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Forty-seven patients enrolled (44 assessable patients). Main inclusion criteria were histologically or cytologically confirmed epithelial cancer of the ovary, fallopian tube, or peritoneum (any stage, grade 2 to 3 if stage I) and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) or elevated CA-125 (&gt; 70 U\/mL) in patients without measurable disease. Patients received nab-paclitaxel 260 mg\/m<jats:sup>2<\/jats:sup> administered intravenously for 30 minutes on day 1 of a 21-day cycle for six cycles or until disease progression. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Median age was 65.5 years; 76% of patients had stage IIIC or IV disease, 81% had Eastern Cooperative Oncology Group performance status of 0, and 94% had prior surgery. For assessable patients, the objective response rate (ORR) was 64% (15 complete responses [CR] and 13 partial responses [PR] among 44 assessable patients). In patients evaluated with RECIST only, the ORR was 45% (one CR and four PR of 11 patients). In patients with only elevated CA-125, ORR was 82% (seven CRs and two PRs of 11 patients). In patients meeting both RECIST and CA-125 criteria, the ORR was 64% (seven CRs and seven PRs of 22 patients). Median time to response was 1.3 months (range, 0.5 to 4.8 months). Estimated median progression-free survival was 8.5 months. The most frequent grade 3 to 4 treatment-related toxicities were neutropenia (24%) and neuropathy (9%). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Nab-paclitaxel is active in this group of patients with recurrent ovarian, peritoneal, or fallopian tube cancer. The ORR was 64%. Toxicities were manageable. Further studies of nab-paclitaxel in combination with platinum are warranted. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2008.18.9548","type":"journal-article","created":{"date-parts":[[2009,2,18]],"date-time":"2009-02-18T04:09:09Z","timestamp":1234930149000},"page":"1426-1431","source":"Crossref","is-referenced-by-count":62,"title":["Phase II Evaluation of Nanoparticle Albumin\u2013Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer"],"prefix":"10.1200","volume":"27","author":[{"given":"Michael G.","family":"Teneriello","sequence":"first","affiliation":[{"name":"From US Oncology Research, Houston; Texas Oncology, Austin; Northwest; Texas Oncology, Waco; Texas Oncology, Fort Worth, TX; and Gynecologic Oncology, Portland, OR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"Tseng","sequence":"additional","affiliation":[{"name":"From US Oncology Research, Houston; Texas Oncology, Austin; Northwest; Texas Oncology, Waco; Texas Oncology, Fort Worth, TX; and Gynecologic Oncology, Portland, OR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Crozier","sequence":"additional","affiliation":[{"name":"From US Oncology Research, Houston; Texas Oncology, Austin; Northwest; Texas Oncology, Waco; Texas Oncology, Fort Worth, TX; and Gynecologic Oncology, Portland, OR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Encarnacion","sequence":"additional","affiliation":[{"name":"From US Oncology Research, Houston; Texas Oncology, Austin; Northwest; Texas Oncology, Waco; Texas Oncology, Fort Worth, TX; and Gynecologic Oncology, Portland, OR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Hancock","sequence":"additional","affiliation":[{"name":"From US Oncology Research, Houston; Texas Oncology, Austin; Northwest; Texas Oncology, Waco; Texas Oncology, Fort Worth, TX; and Gynecologic Oncology, Portland, OR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Messing","sequence":"additional","affiliation":[{"name":"From US Oncology Research, Houston; Texas Oncology, Austin; Northwest; Texas Oncology, Waco; Texas Oncology, Fort Worth, TX; and Gynecologic Oncology, Portland, OR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi A.","family":"Boehm","sequence":"additional","affiliation":[{"name":"From US Oncology Research, Houston; Texas Oncology, Austin; Northwest; Texas Oncology, Waco; Texas Oncology, Fort Worth, TX; and Gynecologic Oncology, Portland, OR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Williams","sequence":"additional","affiliation":[{"name":"From US Oncology Research, Houston; Texas Oncology, Austin; Northwest; Texas Oncology, Waco; Texas Oncology, Fort Worth, TX; and Gynecologic Oncology, Portland, OR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Asmar","sequence":"additional","affiliation":[{"name":"From US Oncology Research, Houston; Texas Oncology, Austin; Northwest; Texas Oncology, Waco; Texas Oncology, Fort Worth, TX; and Gynecologic Oncology, Portland, OR."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5090"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.153"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh323"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.12.043"},{"key":"B8","first-page":"285","volume":"26","author":"Balbi GC","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.09.021"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.10.011"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.09.023"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1634"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2007.n.049"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.8605"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B19","first-page":"2009","volume":"361","author":"Parmar MK","year":"2003","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0913"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1584"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120023765"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.082"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.18.9548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:29:18Z","timestamp":1653521358000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.18.9548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,20]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,3,20]]}},"alternative-id":["10.1200\/JCO.2008.18.9548"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.18.9548","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,20]]}}}